Mojgan Karimi Zarchi; Abolfazl Mehdizadeh Kashi; Leila Allahqoli; Razieh Sadat Tabatabai; Farimah Shamsi; Nafiseh Hashemian Asl
Volume 4, Issue 2 , May and June 2019, , Pages 57-61
Abstract
Background & Objective: This study investigated the recurrence and survival rates of patients with borderline ovarian tumors in Yazd in the last 10 years.
Materials & Methods: This census survival study was performed on 24 patients with borderline ovarian tumors who referred to hospitals ...
Read More
Background & Objective: This study investigated the recurrence and survival rates of patients with borderline ovarian tumors in Yazd in the last 10 years.
Materials & Methods: This census survival study was performed on 24 patients with borderline ovarian tumors who referred to hospitals affiliated to Yazd University of Medical Sciences from 2006 to 2016. A data collection checklist was used as a measurement tool and was completed by the researcher by reviewing the subjects’ medical records. The questionnaire included age, infertility, the number of delivery, contraceptive use, body mass index, time of diagnosis, time to start the treatment, whether alive or not, stage of the disease, the type of pathology, the type of surgery, and postoperative treatment. Data was analyzed by SPSS 16 using descriptive statistics.
Results: The mean age of these 24 patients was 33.58±10.61 and the mean recurrence time was 14±2 months. Sixteen (66.7%) patients had serous tumors and 8 (33.3%) patients had mucinous tumors. Among them, 18 (75%) patients underwent a hysterectomy, 2 (8.3%) patients underwent an oophorectomy and 4 (16.7%) patients underwent both total abdominal hysterectomy (TAH) and oophorectomy. Of the 24 studied patients, 4 patients (16.7%) received medicinal treatment (clomiphene citrate, HCG, HMG) after surgery. Three patients experienced recurrences, all in the contralateral ovary.
Conclusion: The recurrence time of epithelial borderline ovarian tumor was 14±2 months. There was no significant relationship between postoperative medicinal treatment and the recurrence rate.
Azamsadat Mousavi; Mahshid Shooshtari; Setare Nassiri; Abas Ali Aipour; Setare Akhavan; Narges Zamani
Volume 2, Issue 4 , November and December 2017, , Pages 1-5
Abstract
Background: Currently, the prevalence of borderline ovarian tumors (BOT) is increasing, and given the higher diagnosis in the third and fourth decades of life, fertility sparing procedures are widely used. There are important consequences in females with borderline ovarian tumors and number of effective ...
Read More
Background: Currently, the prevalence of borderline ovarian tumors (BOT) is increasing, and given the higher diagnosis in the third and fourth decades of life, fertility sparing procedures are widely used. There are important consequences in females with borderline ovarian tumors and number of effective factors on recurrence and fertility rate.
Methods: In this cohort study, the required information was collected from a file of 43 patients with final pathologic diagnosis of borderline ovarian tumor, who had undertaken fertility sparing surgery at Imam Khomeini Hospital, Tehran University of Medical Sciences, and recurrence rate, fertility rate, and the effect of different variables were studied.
Results: There were significant correlations between oral contraceptive pill (OCP) consumption, serous pathology, micro invasion in pathology, advanced stages, and recurrence rate of BOT, while this relationship was not found between parity, surgical methods (laparotomy and laparoscopy), surgical techniques (cystectomy and USO), papillary projection, and recurrence rate.
Conclusions: Although the recurrence rate was higher in the current research when compared to other previous studies, yet only in one patient, the pattern of recurrence was invasive epithelial carcinoma, thus in the current study the overall survival did not seem to change. The results of this study on fertility rate are comparable to other studies on this issue. Therefore, these methods are recommended for young patients and emphasis should be place on follow-up.
Setareh Akhavan; Azamsadat Mousavi; Abbas Alibakhshi
Volume 1, Issue 1 , May and June 2016
Abstract
Borderline ovarian tumors (BOT) consist of epithelial ovarian lesions that express cytological features of malignancy, but unlike malignant ovarian tumors, do not show obvious stromal invasion. The tumor incidence is between 1.8 and 4.8 per 100,000 females per year. The two major groups of BOT include ...
Read More
Borderline ovarian tumors (BOT) consist of epithelial ovarian lesions that express cytological features of malignancy, but unlike malignant ovarian tumors, do not show obvious stromal invasion. The tumor incidence is between 1.8 and 4.8 per 100,000 females per year. The two major groups of BOT include serous BOT (S-BOT) and mucinous BOT (M-BOT). S-BOTs are divided into two categories: tumors limited to ovary and tumors spreading outside the ovary. M-BOTs are divided into two categories. The more common type is intestinal that constitutes 85% of cases and the second type is endocervical or Mullerian. Mullerian M-BOTs is bilateral in 40% of cases, while it is accompanied by pelvic endometriosis in 20-30% of patients. Microscopic examination by intraoperative frozen section is necessary because macroscopic view of ovarian tumors alone is not reliable. It is better to perform conservative surgery until the final report is ready in patients who wish to preserve their fertility. It is hard to differentiate them based on clinical characteristics. Values of tumor markers including CA125, CA19-9 and CEA in diagnosis of BOT are confirmed. Standard treatment of BOT is surgery as is the case with invasive epithelial ovarian cancer. In the majority of patients referred for BOT, since there is no suspicion of malignancy, staging is not performed. In these cases, making decision to repeat surgery and staging depend on factors such as the type of histology, abdominal exploration results in the previous surgery and probability of the presence of residual tumor.
